Venous thromboembolism, factor V Leiden, and methylenetetrahydrofolate reductase in a sickle cell anemia patient

Pediatric Hematology and Oncology

Volumn 16, Issue 5, 1999, Pages 469-472

  Koren, Ariel ^a,b   Zalman, Lucia ^a   Levin, Carina ^a   Hana, Manhal Abu ^a   Mader, Rivka ^a   Shalev, Stavit ^a  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Activated protein C resistance; Factor V Leiden; Methylenetetrahydrofolate reductase (MTHFR); Sickle cell anemia; Thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5 LEIDEN; FOLIC ACID; HEMOGLOBIN; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; FEMALE; HEMIPLEGIA; HETEROZYGOSITY; HUMAN; ORAL DRUG ADMINISTRATION; PHLEBOGRAPHY; RISK FACTOR; SICKLE CELL ANEMIA; SPLENECTOMY; THROMBOEMBOLISM; THROMBOPHILIA;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANEMIA, SICKLE CELL; FACTOR V; FEMALE; HETEROZYGOTE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; VENOUS THROMBOSIS;

EID: 0032840099     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800199277047     Document Type: Article

References (13)

1. Serjeant GR. The Nervous System. In: Sickle Cell Disease. New York: Oxford Medical Publications; 1985:233-245.
2. Dahlback B, Carlsson M, Stevenson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1008.
3. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Vertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503-1506.
4. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332:912-917.
5. 506→ Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
6. Wright JG, Cooper P, Malia RG, Kulozik AE, Vetter P, Thomas P, Preston FE. Activated protein C resistance in homozygous sickle cell disease. Br J Haematol. 1997;96:854-856.
7. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood. 1997;90:1-11.
8. Virchow R. Phologose und Thrombose in Gefässystem. In: Gesammelle Abhandlungen zur Wissenschaflichen Medicin. Frankfurt: Von Meidinger Sohn; 1856;436-458.
9. Hebbel RP, Yamada O, Moldow CF, Jacob HS, White JG, Eaton JW. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980;65:154-160.
10. Adragna NC, Fonseca P, Lank PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood, 1994;83:553-560.
11. Abildgaard GF, Simone JV, Schulman I. Factor VIII (antiheamophilic factor) activity in sickle-cell anaemia. Br J Haematol. 1967;13:19-27.
12. Rickles FR, O'Leary DS. Role of coagulation system in pathophysiology of sickle cell disease. Arch Int Med. 1974;133:635-641.
13. Powars DR, Schroeder WA. Progress in the natural history studies of the clinical severity of sickle cell disease: epidemiologic aspects. In: Caughey WS, ed. Biochemical and Clinical Aspects of Hemoglobin Abnormalities. New York: Academic; 1978:151-164.